We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




20-Minute POC Test to Diagnose STIs from Rectal and Throat Swabs

By LabMedica International staff writers
Posted on 09 Jun 2023
Print article
Image: Linear dichroism technology provides accurate results and measures multiple targets simultaneously (Photo courtesy of Linear Diagnostics)
Image: Linear dichroism technology provides accurate results and measures multiple targets simultaneously (Photo courtesy of Linear Diagnostics)

Every day, over a million new cases of sexually transmitted infections (STIs) are identified across the globe, making diseases such as gonorrhea and Chlamydia significant health concerns. Although Chlamydia is the most frequently diagnosed STI, gonorrhea cases have also been on the rise. The World Health Organization (WHO) has reported a swift increase in multi-drug resistant gonorrhea, with almost all confirmed treatment failures linked to pharyngeal infections, impacting the throat. Traditional tests involve identifying DNA from swabs or urine samples, which require lab processing and could result in delays from several days to weeks between testing and result delivery. The extraction of DNA from rectal or pharyngeal swabs, however, presents more difficulties Now, a new testing platform technology is being optimized and validated to diagnose STIs from rectal and pharyngeal (throat) swabs.

Linear Diagnostics (Birmingham, UK), a University of Birmingham (Birmingham, UK) spinout, has received funding from the National Institute for Health and Care Research (NIHR, London, UK) to optimize and validate its LDx-CTNG platform technology. This innovative approach utilizes linear dichroism, where a beam of polarized light detects multiple targets from a single sample. The process works by detecting a shift in the plane of polarized light when a target is bound to a detector. Various molecular recognition methods can be used on the detector molecules to measure the target analytes of interest, such as using antibodies to detect antigens or oligonucleotides to capture corresponding target DNA sequences.

Linear Diagnostics' linear dichroism detection technology can identify short, rapidly synthesized DNA strands, enabling the utilization of EXPAR, an ultrafast DNA amplification method. This has drastically reduced the result delivery time compared to traditional PCR and simplified the necessary hardware due to the isothermal nature of EXPAR, which does not require complex heating and cooling cycles. The incorporation of dyes for multiplexing that absorb in the visible light spectrum has facilitated the use of affordable optical components, enabling the device to be miniaturized to a fully portable size. Moreover, the system can be operated using an internal rechargeable battery, eliminating dependence on main power sources or computer access. By pairing linear dichroism with a disposable cartridge and instrument, it is possible to perform simple point-of-care testing. A proof-of-concept study has already indicated that this technology can provide rapid and accurate diagnostic testing.

“For STIs, the rapidity of the testing procedure is key, as patients prefer to get test results quickly and start treatment immediately,” said Brendan Farrell, Chairman of Linear Diagnostics. “We are aiming to produce a testing platform that will meet the WHO stipulations of being easy to use with minimal training, so people can present for testing and collect their treatment in a single visit.”

Related Links:
Linear Diagnostics 
University of Birmingham 
NIHR 

Gold Member
Troponin T QC
Troponin T Quality Control
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Blood Gas and Chemistry Analysis System
Edan i500
New
Epstein-Barr Virus Test
Mononucleosis Rapid Test

Print article

Channels

Clinical Chemistry

view channel
Image: Professor Nicole Strittmatter (left) and first author Wei Chen stand in front of the mass spectrometer with a tissue sample (Photo courtesy of Robert Reich/TUM)

Mass Spectrometry Detects Bacteria Without Time-Consuming Isolation and Multiplication

Speed and accuracy are essential when diagnosing diseases. Traditionally, diagnosing bacterial infections involves the labor-intensive process of isolating pathogens and cultivating bacterial cultures,... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.